Dovato (Dolutegravir Sodium/Lamivudine) Patent Expiration, LOE Window & CMS Spending

Dovato (Dolutegravir Sodium/Lamivudine) by GSK: FDA Orange Book core substance LOE 2030-06-08 (last listed 2031-01-24), 0 AB generics, $839.2M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN211994 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-06-08
Last Listed Patent or Exclusivity Date2031-01-24
Orange Book Patents (*PED Extensions)5 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$839.2M
2024 Medicare Part D Spend$541.1M
2024 Medicaid Spend$298.1M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 17.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.